CytomX CFO Carlos Campoy takes temporary leave; VP Chris Ogden to act as interim principal accounting officer

CytomX Therapeutics, Inc.

CFO Carlos Campoy begins temporary personal leave effective Feb 14, 2022, but remains CFO and principal financial officer.
Chris Ogden, VP Finance and Accounting, designated as interim principal accounting officer.
Ogden's annual base salary set at $315,270 with discretionary bonus target of 30% of salary.
Ogden has severance agreement providing up to 9 months base salary plus benefits and prorated bonus.
Ogden joined CytomX in Aug 2021 after 15 years at Eli Lilly, most recently as CFO of Lilly's diabetes division.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Chris Ogden

interim principal accounting officer

CTMX · CytomX Therapeutics, Inc.

Effective: 2022-02-14
Filed: February 14, 2022, 6:59 PM ET

In connection with Mr. Campoy’s personal leave of absence, the Company’s Board of Directors designated Chris Ogden, the Company’s Vice President, Finance and Accounting, to assume the responsibilities of interim principal accounting officer, effective February 14, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Chris Ogden was appointed as interim principal accounting officer at CytomX Therapeutics, Inc..

Action: designated
Role: interim principal accounting officer

Exact text from the filing

In connection with Mr. Campoy’s personal leave of absence, the Company’s Board of Directors designated Chris Ogden, the Company’s Vice President, Finance and Accounting, to assume the responsibilities of interim principal accounting officer, effective February 14, 2022.

View on SEC.gov

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-041752

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.